The Baiya vaccine, a herbal Covid-19 vaccine under development in Thailand, is set to begin Phase 1 clinical trials this month. The Bangkok Post reports that the vaccine is being developed by Baiya Phytopharm at Chulalongkorn University in Bangkok. Company founder Waranyoo Phoolcharoen said human trials could begin after Thailand’s Food and Drug Administration completes reviewing information about the manufacturing process.
Subject to the success of clinical trials, the vaccine will go into production next year and, if all goes according to plan, is expected to be rolled out by the third quarter of 2022. According to the Bangkok Post report, the Baiya vaccine uses a strain Australian tobacco that has low levels of nicotine. The leaves are used as a host to grow a genetically modified protein. This protein is then removed from the leaves and used to produce a Covid-19 vaccine that produces antibodies against the virus.
Meanwhile, Baiya Phytopharm chief executive Suthira Taychakhoonavudh said the company also hopes to develop a second-generation vaccine to provide even stronger protection, but says it depends on the results of phase 1 trials. that she is convinced that Thailand has great potential for vaccine research and development.
THE SOURCE: Bangkok Post
Get more from The Thaiger
Download our app on Android Where ios
Give your opinion on our Thailand forums
Subscribe to our daily email newsletter
?? Subscribe / To rejoin YouTube for daily broadcasts
Like / Follow us on Facebook
Follow us on Twitter
Follow us on Instagram